Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Bridgebio pharma, inc. save search
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 65.5%
H: 7.78%
C: -8.17%
velocity positive results achondroplasia phase 2
BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
Published: 2023-03-03 (Crawled : 13:00) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.92%
H: 1.82%
C: -1.0%
achondroplasia phase 2
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 3.77%
H: 0.45%
C: -10.34%
bbp-418 pharma results study phase 2
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia
Published: 2022-07-26 (Crawled : 13:00) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 8.43%
H: 0.0%
C: -22.32%
pharma trial positive results phase 2 achondroplasia
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Published: 2022-04-03 (Crawled : 16:20) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
| Email alert
Add to watchlist
pharma results phase 2
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
phase 2 muscular dystrophy pos positive pharma
BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2022-03-11 (Crawled : 12:30) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 3.48%
H: 0.0%
C: 0.0%
phase 2 muscular dystrophy
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease
Published: 2021-11-03 (Crawled : 12:00) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.2%
H: 0.0%
C: 0.0%
disease phase 1 gene therapy therapy trial phase 2
BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants
Published: 2021-10-01 (Crawled : 22:00) - prnewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
| Email alert
Add to watchlist
urine phase 2 blood phase 2b trial
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors
Published: 2021-08-25 (Crawled : 12:00) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.1%
H: 1.34%
C: 0.84%
phase 2 solid tumors cancer trial phase 2b
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2021-02-19 (Crawled : 13:00) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 3.37%
H: 4.94%
C: 1.03%
phase 2 trial
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.